(Received for publication July 13, 1999) DNAtopoisomerase II is a nuclear enzyme that alters DNA conformation through a concerted breakage and rejoining of DNA strands, thereby controlling the topological state of DNA. Topoisomerase II has been shown to be the primary cellular target for a number of clinically important antitumor agents with diverse and unrelated chemical structure1^. These antitumor drugs, referred to as "topoisomerase II poisons", trap the enzyme in an intermediate complex with DNAwhich prevents the final rejoining step of the reaction and results in increased DNAstrand breaks2). Nowit is generally accepted that the ability to form a cleavable complex with topoisomerase II is responsible for the antitumor activity of these drugs3).
In order to identify a specific newtopoisomerase II Figure 1 . UCT1072M1was a hydroxyl derivative of versicolorin B that is known as an one of intermediates in aflatoxin biosynthesis pathway7). UCT1 072M3 was a diastereomer of UCT1072M2. The stereochemistry ofUCT1072M3has not yet determined, but NOEexperiments indicated the putative structure shown in Figure 1 . The details of structure determination and chemical properties of the UCT1072s will be reported elsewhere.
The effect of the UCT1072s on mammalian topoisomerase II was tested using the biochemical assay4) and the cellular assay system8). The topoisomerase II mediated DNAcleavage activity of the UCT1072s was examined in vitro using purified calf thymus topoisomerase II and plasmid pBR322 DNA. Fig. 2A (5600) 459 (8400) 3410, 1628, 1308, 1296, 3420, 1628, 1608, 1394, 1190, 1024 1385, 1309, 1288 Yellow powder was significantly different from that of its diastereomer UCT1072M2. This observation showed the importance of stereochemistry on the moiety fused together anthraquinone skeleton. We next examined the induction of covalent protein-DNA complex by these drugs in HeLa S3 cells using K+/SDS precipitation assay. All of the tested compounds induced complex formation in dose dependent manner (Fig. 2B) . A good correlation between the topoisomerase II mediated DNAcleavage activity in vitro and the activity on the protein-DNA complex formation in cells indicated that the UCT1072s stabilize the topoisomerase II-1047 DNAcleavable complex in cells. Furthermore, the potency of cytotoxic activity against HeLa S3 or Lu-65 cells shown in Table 2 was consistent with the data obtained by these topoisomerase II-based assay systems. On the basis of these results we suggest that the UCT1072s act as the topoisomerase II poison in cells and this mode of action contribute to the cytotoxic activity of these compounds against tumor cells. In spite of showing more potent activity than a known topoisomerase II poison VP-16 in vitro (Percentage of linear DNAwas 35% at 50 jdu VP-16 in the same assay described in Fig. 2A.) , UCT1072M1 showed weaker cytotoxic activity than VP-1 6 at 72 hours-exposure ( Table 2 ). It is presumed that UCT1072M1 might be unstable in cells, because the comparable cytotoxic activity of UCT1072M1to VP-16 was observed when cells were incubated with these antibiotics for 1 hour (Table 2 ). UCT1072M1 was explored to examine antitumor activity in vivo. Following daily i.p. treatment (38mg/kg/day, days 1-5) of UCT1072M1 to mice bearing the murine tumor sarcoma 180, a moderate decrease (T/C-0.5) in tumor volume in vivo was observed. Thus, this class of antibiotic could be a family of naturally occurring new lead compounds for anticancer chemothrapy, which target topoisomerase II in tumor cells. 
